内科理论与实践

内科理论与实践 >

2022 , Vol. 17 >Issue 06: 428 - 434

DOI: https://doi.org/10.16138/j.1673-6087.2022.06.002

论著

低剂量索拉非尼联合全反式维A酸诱导野生型Fms样酪氨酸激酶3的急性髓系白血病细胞分化

展开
  • 1.上海交通大学医学院附属瑞金医院上海血液学研究所，上海 200025
    2.上海交通大学医学院附属第六人民医院血液科，上海 200233

收稿日期: 2022-08-02

  网络出版日期: 2023-02-27

基金资助

上海市科学技术委员会科研计划项目(17ZR1417100)

收起

Low-dose sorafenib combined with all-trans retinoic acid induces differentiation of acute myeloid leukemia cells with wild type Fms like tyrosine kinase 3

Expand
  • 1. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Hematology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

Received date: 2022-08-02

  Online published: 2023-02-27

Fold

摘要

目的：研究低剂量索拉非尼与全反式维A酸（all-trans retinoic acid, ATRA）联合，对野生型Fms样酪氨酸激酶3（Fms like tyrosine kinase3, FLT3）的急性髓系白血病（acute myeloid leukemia, AML）细胞的效应及机制。方法：以野生型FLT3的AML细胞系HL-60、U937以及ATRA耐药的HL-60细胞系——HL-60Res为体外模型，以细胞表面分化抗原CD11b和形态学观察评估细胞分化；应用蛋白质印迹法研究Raf蛋白激酶、促分裂原活化的蛋白激酶（mitogenactivated protein kinase, MEK）和胞外信号调节激酶（extracellular signal-regulated kinase, ERK）的活化状态、PU.1、C/增强子结合蛋白（enhancer-binding protein, EBP）β和C/EBPε的蛋白含量。结果：低剂量（0.1~0.5 μmol/L）索拉非尼促进ATRA诱导HL-60、U937和HL-60Res 3株细胞系分化。两药联合活化Raf、MEK和ERK，并上调PU.1、C/EBPβ和C/EBPε的蛋白含量，MEK的特异性抑制剂曲美替尼可抑制两药诱导的细胞分化、MEK/ERK活化以及PU.1、C/EBPβ和C/EBPε的蛋白含量上调。结论：索拉非尼与ATRA联合，通过Raf/MEK/ERK通路上调PU.1、C/EBPβ和C/EBPε的蛋白含量，诱导野生型FLT3的AML细胞分化。

关键词： 索拉非尼; 全反式维A酸; 细胞分化; 急性髓系白血病

本文引用格式

卢昊, 奚会民, 李璐, 蔡循 . 低剂量索拉非尼联合全反式维A酸诱导野生型Fms样酪氨酸激酶3的急性髓系白血病细胞分化[J]. 内科理论与实践, 2022 , 17(06) : 428 -434 . DOI: 10.16138/j.1673-6087.2022.06.002

Abstract

Objective To explore the effect and the mechanisms of the combination of low-dose sorafenib and all-tran retinoic acid (ATRA) in acute myeloid leukemia (AML) cells with wild type Fms like tyrosine kinase 3 (FLT3). Methods The wild type FLT3 AML cell lines HL-60, U937 and the ATRA-resistant HL-60 cell line, HL-60Res were used as in vitro models. The cell differentiation was evaluated with cell surface differentiation antigen CD11b and cellular morphology. The activation of Raf, mitogenactivated protein kinase (MEK) and extracellular signal-regulated kinase (ERK), the protein expression levels of PU.1, C/EBPβ and C/EBPε were measured by Western blotting assay. Results Low dose (0.1~0.5 μmol/L) sorafenib enhanced ATRA-induced differentiation in all three cell lines studied. The combination activated Raf, MEK and ERK, and up-regulated the levels of C/EBPβ, C/EBPε and PU.1. Addition of trametinib, a MEK specific inhibitor, suppressed the differentiation induced by sorafenib and ATRA, preventing the activation of MEK/ERK and up-regulation of the levels of C/EBPβ, C/EBPε and PU.1. Conclusions The combination of low-dose sorafenib and ATRA induced differentiation of AML cells with wild type FLT3 via RAF/MEK/ERK-mediated up-regulation of the protein levels of C/EBPβ, C/EBPε and PU.1.

Key words： Sorafenib; All-trans retinoic acid; Differentiation; Acute myeloid leukemia

参考文献

[1] Medinger M, Passweg JR. Acute myeloid leukaemia genomics[J]. Br J Haematol, 2017, 179(4): 530-542.
[2] D?hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia[J]. N Engl J Med, 2015, 373(12): 1136-1152.
[3] Ferrara F, Vitagliano O. Induction therapy in acute myeloid leukemia: is it time to put aside standard 3+7?[J]. Hematol Oncol, 2019, 37(5):558-563.
[4] Tallman MS. Differentiating therapy in acute myeloid leukemia[J]. Leukemia, 1996, 1010(8):1262-1268.
[5] Gong L, Giacomini MM, Giacomini C, et al. PharmGKB summary: sorafenib pathways[J]. Pharmacogenet Genomics, 2017, 27(6): 240-246.
[6] Antar A, Otrock ZK, El-Cheikh J, et al. Inhibition of FLT3 in AML: a focus on sorafenib[J]. Bone Marrow Transplant, 2017, 52(3): 344-351.
[7] Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia[J]. Leuk Lymphoma, 2008, 49(12): 2246-2255.
[8] Yalniz F, Abou Dalle I, Kantarjian H, et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib[J]. Am J Hematol, 2019, 94(9): 984-991.
[9] Battipaglia G, Massoud R, Ahmed SO, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(8): 506-508.
[10] Roolf C, Dybowski N, Sekora A, et al. Phosphoproteome analysis reveals differential mode of action of sorafenib in wildtype and mutated FLT3 acute myeloid leukemia (AML) cells[J]. Mol Cell Proteomics, 2017, 16(7): 1365-1376.
[11] Fouladi F, Jehn LB, Metzelder SK, et al. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation[J]. Leuk Lymphoma, 2015, 56(9): 2690-2698.
[12] Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF[J]. Nature, 2010, 464(7287): 427-430.
[13] Miranda MB, Xu H, Torchia JA, et al. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway[J]. Leuk Res, 2005, 29(11): 1293-306.
[14] Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest[J]. Cancer Res, 1998, 58(14): 3163-3172.
[15] Wang R, Xia L, Gabrilove J, et al. Sorafenib inhibition of Mcl-1 accelerates ATRA-induced apoptosis in differentiation-responsive AML cells[J]. Clin Cancer Res, 2016, 22(5): 1211-1221.
[16] Ma HS, Greenblatt SM, Shirley CM, et al. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo[J]. Blood, 2016, 127(23): 2867-2878.
[17] R?llig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial[J]. Leukemia, 2021, 35(9): 2517-2525.
[18] Strumberg D, Richly H, Hilger RA, et al. Phase Ⅰ clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors[J]. J Clin Oncol, 2005, 23(5): 965-972.
[19] Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation[J]. Leukemia, 2007, 21(7): 1363-1377.
[20] Li ZY, Liang C, Ding M, et al. Enzastaurin enhances ATRA-induced differentiation of acute myeloid leukemia cells[J]. Am J Transl Res, 2020, 12(12): 7836-7854.
[21] Lee S, Shuman JD, Guszczynski T, et al. RSK-mediated phosphorylation in the C/EBPβ leucine zipper regulates DNA binding, dimerization, and growth arrest activity[J]. Mol Cell Biol, 2010, 30(11): 2621-2635.
[22] Lu J, Wu DM, Zheng YL, et al. Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein β-mediated inflammatory response and oxidative stress[J]. J Immunol, 2013, 190(7), 3466-3479.
[23] Murakami M, Ito H, Hagiwara K, et al. Sphingosine kinase 1/S1P pathway involvement in the GDNF-induced GAP43 transcription[J]. J Cell Biochem, 2011, 112(11): 3449-3458.
[24] Yoshida H, Ichikawa H, Tagata Y, et al. PML-retinoic acid receptor alpha inhibits PML Ⅳ enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation[J]. Mol Cell Biol, 2007, 27(16): 5819-5834.
[25] Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression[J]. Blood, 2006, 107(8): 3330-3338.
Options
文章导航

/

〈 〉